Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2021-06-25 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-06-25 English
Publication of Annual Report and Accounts
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3,745 characters) from MaxCyte, Inc. titled 'Publication of Annual Report and Accounts'. It explicitly states that the company has published its Annual Report and provides a link to the company's website to view it. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore falls under the Report Publication Announcement (RPA) category.
2021-06-16 English
Stockholder Circular and Notice of Special Meeting
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding the publication of a stockholder circular and the notice of a special meeting. It explicitly states that the circular has been published and provides a link to where it can be accessed. Following the 'Menu vs Meal' rule, this document is an announcement of a report/circular rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA).
2021-06-16 English
Maxcyte Appoints Two New Non-Executive Directors
Board/Management Information Classification · 95% confidence The document is an official announcement from MaxCyte, Inc. regarding the appointment of two new non-executive directors to its board. It also includes a mandatory disclosure of share options granted to these directors, formatted as a 'Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities' (PDMR). While it contains director dealing information, the primary purpose of the announcement is the appointment of new board members, which falls under the 'Board/Management Information' category.
2021-06-15 English
Regulatory Filings 2021
Regulatory Filings
2021-06-10 English
Total Voting Rights
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from MaxCyte, Inc. regarding the issuance of new shares of common stock following the exercise of share options. It explicitly provides the updated total issued stock capital and the number of voting rights, which shareholders use to calculate their interest in the company. This type of disclosure is a standard 'Total Voting Rights' announcement, which falls under the category of share capital changes and issuance.
2021-06-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.